Multiple Sclerosis patient

Neurology & Immunology

Hundreds of millions of people worldwide are affected by neurological disorders, from Alzheimer's and Parkinson’s disease, multiple sclerosis and epilepsy, to migraine, brain injuries and neuroinfections.1

We are determined to help people living with neurological disorders through the development of innovative investigational approaches to new treatments, built on patient insights, therapy area expertise and cutting-edge science and technology.

With 18 years’ commitment in multiple sclerosis, we have relentlessly worked to improve the lives of the 2.3 million people worldwide living with this serious, lifelong neuro-degenerative disease. Since the launch of our multiple sclerosis portfolio 2012, we have rapidly emerged as a leader in MS, bringing two important therapies to patients in more than 80 countries around the world. 

We know there is still more work to be done, and we are committed to advancing clinical research to improve all treatment dimensions of the disease.

Inspired by patients around the world

Catherine, rheumatoid arthritis, United States
Multiple sclerosis patient
Multiple sclerosis patient

Above from left to right: Catherine, rheumatoid arthritis, United States; Cassie, multiple sclerosis, Australia; Dave, multiple sclerosis, United Kingdom

Pushing the Boundaries in Neurology & Immunology

Our dedication to scientific advancement stems from a drive to reset expectations for better targeted therapies in neurology. With many ongoing research projects, we are determined to better understand the science of neurological diseases in order to develop potential new treatment options to make a real difference to people’s lives. 

We can’t do this alone. That’s why we partner with academic centers, biotechnology and biopharmaceutical companies, patient organizations, communities and individuals to help us respond to the day-to-day challenges of living with a neurological disease. Ultimately, it is our goal to accelerate the development of potential treatments for multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS), and advance science to better serve these communities.

We remain committed to researching new potential solutions for people living with MS. Our clinical focus is on researching mechanisms to stop disease progression across the multiple sclerosis spectrum and reducing the ongoing accumulation of disability.

Our unrelenting commitment to scientific exploration extends to immunology, where our portfolio includes an approved treatment for adults with moderate-to-severe rheumatoid arthritis. We are also studying this compound in other immunological disorders, including polymyalgia rheumatica, giant cell arteritis, polyarticular juvenile idiopathic arthritis and systemic juvenile arthritis. 

Encouraging People with Neurological Diseases to Demand More

The resilience of people living with neurological diseases inspires our work. We are committed to maintaining long-term partnerships with patients, physicians, advocates and researchers, making a significant impact on the unmet needs of those living with neurological disorders like multiple sclerosis. 

  • We believe in more than just hearing the community, we’re committed to listening and taking action.
  • We provide personalized, round-the-clock support programs and guidance for patients and their care partners. 
  • Through our work with leading patient advocacy organizations, we provide educational disease information and resources to equip patients and their care partners to take a proactive approach to managing their care.
  • To us, support means showing up for the community when it matters. We sponsor and participate in awareness and fundraising events across the world each year, engaging face-to-face with patients and the broader community.
  • We are continuously exploring new ways to leverage technology to help advance science and better serve our patient communities.

Learn about treatment options

Multiple sclerosis
Rheumatoid arthritis

1. World Health Organization. What are Neurological Disorders?   Accessed on September 22, 2020.

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies.